Adrenoleukodystrophy Drugs Market

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Adrenoleukodystrophy Drugs Market contains market size and forecasts of Adrenoleukodystrophy Drugs in global, including the following market information:
Global Adrenoleukodystrophy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Adrenoleukodystrophy Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Adrenoleukodystrophy Drugs companies in 2021 (%)
The global Adrenoleukodystrophy Drugs market was valued at 347.6 million in 2021 and is projected to reach US$ 936.8 million by 2028, at a CAGR of 15.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hormone Replacement Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adrenoleukodystrophy Drugs include Bluebird Bio Inc, NeuroVia, Inc., Orpheris, Inc., Minoryx and MedDay Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenoleukodystrophy Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, by Type, 2021 (%)
Hormone Replacement
Transplant
Others
Global Adrenoleukodystrophy Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, by Application, 2021 (%)
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
Global Adrenoleukodystrophy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adrenoleukodystrophy Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Adrenoleukodystrophy Drugs revenues share in global market, 2021 (%)
Key companies Adrenoleukodystrophy Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Adrenoleukodystrophy Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals